If 2015 was the ‘Year of the API’, why is there a Remdesivir shortage six years later?
- Whether it is the production linked incentive or the waiver of duty on
Remdesivir, these are steps that could have been taken six years ago.
- In 2015, the Indian government decided to boost the
manufacturingof API, the most important ingredient in a drug, but the policy remained on paper and as a catchphrase on headlines.
- In fact, since 2015, the year when the government resolved to promote the manufacture of bulk drugs in
India, the imports have only gone up.
In 2021, everyone from the mighty
However, six years ago, the same government had celebrated ‘the year of API’. The acronym stands for active
AdvertisementIn fact, since 2015, the year when the government resolved to promote the manufacture of bulk drugs in India, the imports have only gone up.
The idea was to encourage local manufacturing of APIs on a bigger scale but after six years of stated intent, India is still dependent on China for nearly 70% of its API, also called bulk drugs, needs.
Now, more than a year into the pandemic, drug makers and vaccine makers in India — which proudly carries the tag ‘pharmacy of the world’ — are pleading for access to key raw material. The list includes
There are many factors why API manufacturing hasn’t picked pace in India. The following are the reasons cited by consulting firm PwC.
Respected @POTUS, if we are to truly unite in beating this virus, on behalf of the vaccine industry outside the U.S… https://t.co/MsnowghtBQ— Adar Poonawalla (@adarpoonawalla) 1618562794000
- stricter implementation of pollution control norms, leading to higher costs of manufacturing APIs in India
issues in interpretation of the Drug Price Control Order (DPCO), 2013
- no financial incentives like lower tax, cheaper utilities and land subsidy to lower capex requirement
- lack of large-scale mega parks to manufacture bulk drugs -- collapse of the fermentation industry in India.
The chaos around Remdesivir is one of the examples of how slow the policy wheel moves in India, no matter who is in charge of government. The demand for Remdesivir has been off the charts for a while, for a variety of reasons.
The manufacturing process has been stalled by the lack of APIs but the government did not waive off the customs duty on this crucial import, until April 20, about a year after the drug has been allowed to be used as a last resort for COVID-19 patients.
AdvertisementOf course, the government has approved a ₹6,940 crore production-linked incentive scheme to boost the manufacturing of APIs too, among other pharmaceutical products. The policy was announced as part of the Aatmanirbhar Bharat (self-reliant India) programme, at the peak of the pandemic.
If the same measures had been announced earlier in 2015, when we were celebrating the year of the API, at least a few deaths and some anxiety could have been avoided.
SEE ALSO: Apple will roll out the privacy-oriented iOS 14.5 update next week that has Facebook worried
Netflix co-founder Reed Hastings says India is a 'speculative' investment – talks about pricing experiments and partnership with Jio
All the 'first-time from Apple' announcements from its Spring Loaded Event
Coinbase hires former Google Pay exec to lead India ops, is hiring aggressively and looking for startup acquisitions
- Over One lakh oxygen concentrators cleared by customs from April 24 to May 4
- Check out who all can travel to the US amidst uncertainty in international travel
- Water shortage might be on the way to worsen Delhi's COVID-19 crisis
- Himachal Pradesh government imposes curfew effective from tomorrow till May 16
- A third wave of COVID-19 will surely come and it may spread faster and wider but don't know when, says advisor to the Indian government